Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
- PMID: 29801017
- DOI: 10.1001/jama.2018.3710
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
Erratum in
-
Incorrect Data in Abstract and Text.JAMA. 2018 Jun 19;319(23):2443. doi: 10.1001/jama.2018.7453. JAMA. 2018. PMID: 29922808 No abstract available.
Abstract
Importance: In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men.
Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.
Evidence review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening. The reviews also examined the benefits and harms of PSA-based screening in patient subpopulations at higher risk of prostate cancer, including older men, African American men, and men with a family history of prostate cancer.
Findings: Adequate evidence from randomized clinical trials shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. Potential harms of screening include frequent false-positive results and psychological harms. Harms of prostate cancer treatment include erectile dysfunction, urinary incontinence, and bowel symptoms. About 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and 2 in 3 men will experience long-term erectile dysfunction. Adequate evidence shows that the harms of screening in men older than 70 years are at least moderate and greater than in younger men because of increased risk of false-positive results, diagnostic harms from biopsies, and harms from treatment. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small. The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms.
Conclusions and recommendation: For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. (C recommendation) The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. (D recommendation).
Comment in
-
Shared Decision Making Emphasized for Prostate Screening.Cancer Discov. 2018 Jul;8(7):OF1. doi: 10.1158/2159-8290.CD-NB2018-069. Epub 2018 May 24. Cancer Discov. 2018. PMID: 29794067
-
Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence.JAMA. 2018 May 8;319(18):1866-1868. doi: 10.1001/jama.2018.4914. JAMA. 2018. PMID: 29800999 No abstract available.
-
Guideline: USPSTF recommends against PSA screening except in men 55 to 69 years who express a preference for it.Ann Intern Med. 2018 Sep 18;169(6):JC28. doi: 10.7326/ACPJC-2018-169-6-028. Ann Intern Med. 2018. PMID: 30242401 No abstract available.
Summary for patients in
-
Screening for Prostate Cancer.JAMA. 2018 May 8;319(18):1946. doi: 10.1001/jama.2018.4972. JAMA. 2018. PMID: 29801013 No abstract available.
Similar articles
-
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238. JAMA. 2021. PMID: 34003218
-
Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1. PMID: 30085502 Free Books & Documents. Review.
-
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712. JAMA. 2018. PMID: 29801018 Review.
-
Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.Ann Intern Med. 2013 May 21;158(10):761-769. doi: 10.7326/0003-4819-158-10-201305210-00633. Ann Intern Med. 2013. PMID: 23567643
-
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Aug. Report No.: 08-05121-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Aug. Report No.: 08-05121-EF-1. PMID: 20722160 Free Books & Documents. Review.
Cited by
-
Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).PLoS One. 2024 May 30;19(5):e0303203. doi: 10.1371/journal.pone.0303203. eCollection 2024. PLoS One. 2024. PMID: 38814917 Free PMC article.
-
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.JAMA. 2024 Jun 25;331(24):2084-2093. doi: 10.1001/jama.2024.6695. JAMA. 2024. PMID: 38814624
-
Performance of an ultra-fast deep-learning accelerated MRI screening protocol for prostate cancer compared to a standard multiparametric protocol.Eur Radiol. 2024 May 23. doi: 10.1007/s00330-024-10776-7. Online ahead of print. Eur Radiol. 2024. PMID: 38780766
-
Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial.Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024. Front Oncol. 2024. PMID: 38741776 Free PMC article.
-
Associations between knowledge of health issues and health care satisfaction and propensity to complain: a cross-sectional survey of adult men in Denmark.BMJ Open. 2024 May 6;14(5):e076257. doi: 10.1136/bmjopen-2023-076257. BMJ Open. 2024. PMID: 38719305 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous